<DOC>
	<DOCNO>NCT02142205</DOCNO>
	<brief_summary>The primary objective evaluate safety tolerability natalizumab ( BG00002 , Tysabri® ) study population ( Russian participant relapse remit multiple sclerosis ) . The secondary objective look evaluation severity relapse , hospitalization steroid use requirement ; Expanded Disability Status Scale ( EDSS ) , functional test , quality life self-assessment questionnaire include short form health survey self-assessment questionnaire ( SF-36 ) multiple sclerosis impact scale 29 ( MSIS-29 ) , evidence MRI disease activity , participant free disease activity ( clinical activity and/MRI activity ) anti JC Virus ( JCV ) antibody evaluation .</brief_summary>
	<brief_title>Safety Efficacy Natalizumab ( BG00002 , Tysabri® ) Russian Participants With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Must natalizumab naïve . Must document diagnosis relapse remit form MS define revise McDonald Committee criterion ( Polman et al. , 2011 ) Must least 1 relapse previous year : Must stable disability least 30 day prior enrollment study Must stable symptomatic management disease , specifically spasticity , depression fatigue least 30 day prior enrollment study . Must consider Investigator free sign symptom suggestive Progressive multifocal leukoencephalopathy ( PML ) base medical history , physical examination , laboratory testing . Must willing discontinue remain free concomitant immunosuppressive immunomodulatory treatment ( include IFNbeta Glatiramer Acetate ) treat natalizumab study . Key Medical History : Onset relapse within 50 day prior first infusion . Considered Investigator immunocompromised , base medical history , physical examination , laboratory test due prior immunosuppressive treatment History , available abnormal laboratory result indicative , significiant viral , cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric ( include major depression ) , renal , and/or major disease would preclude administration recombinant humanize antibody immunomodulating agent . The Investigator must rereview subject 's medical fitness participation consider disease would preclude treatment . History malignancy ( subject basal cell carcinoma completely excise prior study entry remain eligible ) Known history human immunodeficiency virus infection hematological malignancy History organ transplantation ( include antirejection therapy ) A clinically significant infectious illness ( e.g . abscess , pneumonia , septicemia ) within 30 day prior Screening Visit . Treatment History : Treatment kind immunosuppressant medication ( e.g. , mitoxantrone , cyclophosphamide , cyclosporine , azathioprine , methotrexate , fingolimod , cladribine ) within 6 month prior Screening Miscellaneous : Female subject postmenopausal least 1 year , surgically sterile ( include tubal ligation ) , unwilling practice effective contraception ( defined Investigator ) study Women breastfeeding , pregnant , plan become pregnant study Other unspecified reason , opinion Investigator and/or Biogen Idec , make subject unsuitable enrollment study . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>